Dogwood Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Dogwood Therapeutics

07/11/2024 14:34

* Dogwood Therapeutics Inc  DWTX.OQ  reported a quarterly
adjusted
loss of $2.05​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of $-1.50.  The mean expectation of three analysts for the
quarter was for a loss of $1.18 per share. Wall Street expected
results to range from $-1.40 to -88 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Dogwood Therapeutics Inc's reported EPS for the quarter
was a
loss of $2.05​.
    * The company reported a quarterly loss of $2.28 million.
    * Dogwood Therapeutics Inc shares had risen by 4.7% this
quarter and lost 69.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 21.6%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for Dogwood
Therapeutics Inc is $25.00 
This summary was machine generated from LSEG data November 7 at
02:34 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -1.18          -2.05          Missed
 Jun. 30 2024      -1.58          -1.25          Beat
 Mar. 31 2024      -1.00          -1.75          Missed
 Dec. 31 2023      -2.25          -1.50          Beat